Lumos Diagnostics Holdings Ltd. · ASX:LDX
Lumos Diagnostics — Q4 FY24 Earnings Presentation
20 slides from Lumos Diagnostics's earnings presentation, Aug 1, 2024
Slide 1: Q4 FY24 Investor Presentation
For personal use only Lumos Diagnostics Holdings Limited Q4 FY24 Investor Presentation 1 August 2024 lumosdiagnostics.com 1
Slide 2: Disclaimer and Important Information
Disclaimer and Important Information This presentation (Presentation) has been prepared solely for informational purposes by Lumos Diagnostics Holdings Limited (Company). The information contained in this document (“Document”) has been prepared by Lumos Diagnostics Holdings Limited (referred to as “
Slide 3: Contents
Contents For personal use only Company Overview Q4 FY24 Highlights Financials Services Update Product Update Key Strategic Priorities Questions 3
Slide 4: Company Overview
For personal use only Company Overview
Slide 5: Company Overview
Company Overview Lumos is a developer and Experienced leadership team For personal use only • Led by Doug Ward (CEO/MD) - industry veteran with over 30 years' in diagnostics manufacturer of connected • Experienced business/technical/commercial leaders also include instrumentation and rapid Barrie La
Slide 6: Lumos Service Offering
Lumos Service Offering 1. Fully-integrated—from design to manufacturing 2. Proprietary reader platform for use in different settings For personal use only Strategic Product Commercial Innovation Development Manufacturing Single-use Multi-use disposable Desktop readers 3. IVD development and manufact
Slide 7: Lumos POC Diagnostic Test Development Engine
Lumos POC Diagnostic Test Development Engine Product Concepts For personal use only DESIGN DEVELOP MANUFACTURE Lumos POC Design Engine Revenue Streams Contract Fees Transfer Price & Margin Sales & IP License Payments from services from manufacturing from own products & other products 7
Slide 8: Q4 FY24 Highlights
For personal use only Q4 FY24 Highlights
Slide 9: Key Highlights from Q4 FY24
Key Highlights from Q4 FY24 For personal use only Key “Phase 1 Milestone” of the fFN Cash receipts of US$7.4 million 2nd consecutive quarter of positive Development Agreement achieved Including US$5.0 million non-refundable net cash flows - US$3.1 million With leading US women’s health company, paym
Slide 10: Financials
For personal use only Financials
Slide 11: Financials - Summary
Financials - Summary (US$ in thousands) REVENUE REVENUE MIX NET CASH GENERATION* For personal use only $4,340 100% $3,117 $4,025 80% $2,012 60% $1,655 40% $1,111 20% 0% Q1FY24 Q2FY24 Q3FY24 Q4FY24 Q1FY24 Q2FY24 Q3FY24 Q4FY24 -$2,777 -$2,763 Commercial Services Products Commercial Services Products Q
Slide 12: Services Update
For personal use only Services Update
Slide 13: Hologic - Strategic Partnership Update
Hologic - Strategic Partnership Update The Agreements build on previous work conducted by Lumos and Hologic and focus on the development of an For personal use only improved version of one of Hologic's leading in-market women's health products, including adapting it for use on Lumos’ proprietary rea
Slide 14: Product Update
For personal use only Product Update
Slide 15: Henry Schein Distribution Agreements
Henry Schein Distribution Agreements For personal use only • FebriDx is a rapid point-of-care respiratory test which delivers results after 10 minutes from a fingerstick blood sample. • Henry Schein is the world’s largest provider of health care solutions to office-based dental and medical practitio
Slide 16: FebriDx Update
FebriDx Update • Reimbursement Amount: PLA Code update • Positive momentum - CMA Panel presentation in June was For personal use only well received, final decision expected Sept 2024 • Partnerships • 25 FebriDx partnerships in FY24: regional distributors and end-user customers • Immediate impact wit
Slide 17: ViraDx Update
ViraDx Update • Distribution For personal use only • 19 ViraDx partnerships FY25 • 3 new distribution agreements in Q4 FY24 • Infection rates • US summer: elevated acute respiratory infections (Covid) • Purchase orders have already provided a robust start to FY25 • Stocking orders • Full season v ha
Slide 18: Key Strategic Priorities
For personal use only Key Strategic Priorities
Slide 19: Key Strategic Priorities
Key Strategic Priorities For personal use only Focus on growing sales of our two in-market proprietary products, FebriDx and ViraDx Building a sustainable and growing pipeline of commercial, revenue-generating projects for both development services and contract manufacturing Deliver on milestones re
Slide 20: lumosdiagnostics.com
For personal use only lumosdiagnostics.com 20
Lumos Diagnostics Holdings — Q4 FY24 Earnings Presentation on 6ix